Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Joining forces globally against drug resistant bacteria

03.04.2014

Antibiotics have saved millions of lives from once deadly infectious diseases. But, misuse of antibiotics and other antimicrobials in humans and animals has led to bacteria evolving resistance.

Today, 3 April 2013 in Brussels, the Joint Programme on Antimicrobial Resistance (JPIAMR) presented its strategic research agenda which outlines the steps that need to be taken to minimise antimicrobial resistance, one of today’s most serious public health threats.

In addition to the 19 countries which include European countries as well as Canada and Israel, already signed up to this initiative, JPIAMR received support from countries ranging from Australia to South Africa during this meeting.

“It’s a worldwide concern that resistance to antimicrobial drugs, which have allowed us to treat or prevent deadly infections and save many lives, especially children, is now spreading all over the world at increased speed, related with the increased mobility of people.

It’s therefore crucial to immediately join forces under one research agenda to achieve a substantial and rapid impact, especially on global health threats like HIV/AIDS, TB and malaria”, said Fulvio Esposito from the Italian Ministry for Education, University and Research.

Coming together globally is indeed crucial as the problem of antimicrobial resistance is so wide that the world now seems to be entering a post-antibiotic era in which sophisticated clinical interventions such as organ transplants, cancer chemotherapy or care for pre-term infants will become far more difficult due the threats of infections with multi-drug resistant bacteria.

Resistance is so widespread that for some groups of bacteria, few antibiotics are effective enough anymore for therapy.

The Strategic Research Agenda (SRA)
JPIAMR has identified six priority topics which form a Strategic Research Agenda (SRA). These topics will give the fight against antibiotic resistance a multidimensional approach. The idea is that these approaches will be translated into new prevention and intervention strategies that improve the public health and wellbeing of populations and delivers economic and societal benefits throughout Europe and beyond.

1. Therapeutics: Improvement of current antibiotics and development of new antibiotics and alternatives for antibiotics, such as vaccines.

2. Diagnostics: Improvement of diagnostics and development of new (rapid) diagnostics to stimulate better use of current antibiotics and support the development and use of new antibiotics and alternatives to antibiotics.

3. Surveillance: Establishment of an international, standardised surveillance programme for AMR and antibiotic use in human, and agricultural settings.

4. Transmission: A comprehensive, multi-disciplinary understanding of the transmission mechanisms by which antibiotic resistance can spread between bacterial populations and between different (animal and human) reservoirs and to translate this knowledge into the development of evidence-based strategies to minimize the spread of resistance.

5. Environment: Assessment of the contribution of pollution of the environment with antibiotics, antibiotic residues and resistant bacteria on the spread of AMR and the development of strategies to minimize environmental contamination by antibiotics and resistant bacteria.

6. Interventions: Study of preventative and control interventions that focus on improved antibiotic stewardship, compliance and prevention of transmission of AMR and to determine and improve their efficacy.

“As this is an active research field and AMR is a very real and present societal challenge, the strategic research agenda will need to stay a living document that is continuously updated to keep pace with developments within research and society, “said Mats Ulfendahl, Swedish Research Council.

Operating at all relevant levels, from the scientific community to research funders and from policy makers and societal stakeholders to industry and SMEs, is the only way to reduce the inappropriate use of antibiotic use both in humans and animals to stop this trend from continuing and to ultimately find a more sustainable way to use antibiotics and treat disease.

Therefore, assisted by European Commission funding, the International Medicines Initiative (IMI), national funding contributions and public-private partnerships, the next step for JPIAMR is to fund research which fit within the six priority areas and which will contribute towards solving the AMR problem.

For more information contact:
Laura Marin, Project Manager, Swedish Research Council, laura.marin@vr.se
Phone: +46 8 546 44 119

Sofia Kuhn, Communications Manager, sofia.kuhn@muninnscience.com
Phone: +32 486 67 39 42

Why JPIAMR?

• Antimicrobial resistance is a real threat to the lives of European citizens.
• Research of antimicrobial resistance in Europe is fragmented and few countries have specific programs dedicated to this field of research.
• 19 Member states have joined forces in the Joint Programme Initiative on Antimicrobial Resistance (JPIAMR) to coordinate the research, in order to allow greater impact and avoid duplication.
• Only by bringing together industry, public health and academic bodies to share experiences and resources across scientific disciplines will we be able to create long term reduction of antimicrobial resistance in Europe.

Aims

• JPIAMR will develop scientific proposals which will lead to sustainable use of antibiotics to treat infectious diseases and to a decrease in the number of patients with resistant infections in Europe.
• It aims to integrate relevant scientific fields across national borders and to create a common Strategic Research Agenda with a shared common vision where the best resources and capabilities are coordinated.
• JPIAMR provides the forum and platform for initiating and coordinating joint actions with stakeholders beyond issuing joint calls.

Objectives

• Find routes for novel antibiotics and new anti-infectious strategies.
• Scientifically validate means to increase the number of patients treated early with the appropriate antimicrobial.
• Provide scientific evidence on ways to reduce the spread of resistant strains.
• Provide scientific evidence on strategies to reduce the number of patients with resistant or MDR strains, at any level of antibiotic consumption.
• Reduce the consumption of antibiotics.

What is joint programming?
Research efforts can be essential to address major societal challenges. In some cases these are so great that national research programmes cannot tackle them effectively on their own. In addition, the vast bulk of research programmes in Europe are run in an isolated way, leading to unwanted fragmentation or ineffectiveness. Joint programming aims to remedy this situation.
Joint programmes aim to pool national research efforts in order to make better use of Europe’s public R&D resources and to tackle common European challenges more effectively in a few key areas.
The ultimate objective is to overcome the fragmentation of national research programmes to address global challenges.
More information www.jpiamr.eu

Weitere Informationen:

http://www.jpiamr.eu project website
http://www.jpiamr.eu/wp-content/uploads/2014/01/JPIAMR-SRA-v1.pdf The Strategic Research Agenda (SRA)

Sofia Kuhn | idw - Informationsdienst Wissenschaft

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>